Breast Cancer Research and Treatment

, Volume 137, Issue 1, pp 23–32 | Cite as

Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer

  • L. Susan Taichman
  • Aaron M. Havens
  • Catherine H. Van Poznak
Invited Review


Current adjuvant treatment modalities for breast cancer that express the estrogen receptor or progesterone receptor include adjuvant anti-estrogen therapies, and tamoxifen and aromatase inhibitors. Bone, including the jaw, is an endocrine-sensitive organ, as are other oral structures. This review examines the potential links between adjuvant anti-estrogen treatments in postmenopausal women with hormone receptor positive breast cancer and oral health. A search of PubMed, EMBASE, CENTRAL, and the Web of Knowledge was conducted using combinations of key terms “breast,” “cancer,” “neoplasm,” “Tamoxifen,” “Aromatase Inhibitor,” “chemotherapy,” “hormone therapy,” “alveolar bone loss,” “postmenopausal bone loss,” “estrogen,” “SERM,” “hormone replacement therapy,” and “quality of life.” We selected articles published in peer-reviewed journals in the English. The authors found no studies reporting on periodontal diseases, alveolar bone loss, oral health, or oral health-related quality of life in association with anti-estrogen breast cancer treatments in postmenopausal women. Periodontal diseases, alveolar bone density, tooth loss, and conditions of the soft tissues of the mouth have all been associated with menopausal status supporting the hypothesis that the soft tissues and bone of the oral cavity could be negatively affected by anti-estrogen therapy. As a conclusion, the impact of adjuvant endocrine breast cancer therapy on the oral health of postmenopausal women is undefined. The structures of the oral cavity are influenced by estrogen; therefore, anti-estrogen therapies may carry the risk of oral toxicities. Oral health care for breast cancer patients is an important but understudied aspect of cancer survivorship.


Aromatase inhibitors Breast cancer Oral health 


  1. 1.
    US Department of Health and Human Services (2000) Oral health in America: a report of the surgeon general. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institute of Health, RockvilleGoogle Scholar
  2. 2.
    NIH (1989) Oral complications of cancer therapies: diagnosis, prevention and treatment consensus statement. 7:1–11. Accessed 1 April 2012
  3. 3.
    National Institute of Dental and Craniofacial Research (2011) Cancer treatment and you: three good reasons to see a dentist before cancer treatment. Accessed 1 April 2012
  4. 4.
    National Institute of Dental and Craniofacial Research (2008) Oral complications of cancer treatment: What the dental team can do. Accessed 1 April 2012
  5. 5.
    McGuire DB (2003) Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 11:435–441PubMedCrossRefGoogle Scholar
  6. 6.
    Epstein JB, Parker IR, Epstein MS et al (2007) A survey of National Cancer Institute-designated comprehensive cancer centers’ oral health supportive care practices and resources in the USA. Support Care Cancer 15:357–362PubMedCrossRefGoogle Scholar
  7. 7.
    Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) SEER cancer statistics review, 1975–2008. National Cancer Institute, Bethesda, MD. Accessed 30 April 2012
  8. 8.
    Sheiham A, Steele JG, Marcenes W et al (1999) The impact of oral health on stated ability to eat certain foods; findings from the National Diet and Nutrition Survey of older people in Great Britain. Gerodontology 16:11–20PubMedCrossRefGoogle Scholar
  9. 9.
    Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology (Williston Park) 16:680–686; discussion 686, 691-692, 695Google Scholar
  10. 10.
    Epstein JB, Parker IR, Epstein MS et al (2004) Cancer-related oral health care services and resources: a survey of oral and dental care in Canadian cancer centres. J Can Dent Assoc 70:302–304PubMedGoogle Scholar
  11. 11.
    Mariotti A (1994) Sex steroid hormones and cell dynamics in the periodontium. Crit Rev Oral Biol Med 5:27–53PubMedGoogle Scholar
  12. 12.
    Leimola-Virtanen R, Salo T, Toikkanen S et al (2000) Expression of estrogen receptor (ER) in oral mucosa and salivary glands. Maturitas 36:131–137PubMedCrossRefGoogle Scholar
  13. 13.
    Karthik SJ, Arun KV, Sudarsan S et al (2009) Evaluation of estrogen receptor and circulating estradiol levels in pre- and postmenopausal women with periodontal disease. J Int Acad Periodontol 11:202–205PubMedGoogle Scholar
  14. 14.
    Khan MN, Khan AA (2008) Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol 15:S30–S40PubMedCrossRefGoogle Scholar
  15. 15.
    National Cancer Institute (2011) Breast cancer statistics. Accessed 1 April 2012
  16. 16.
    Nelson HD, Humphrey LL, Nygren P et al (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288:872–881PubMedCrossRefGoogle Scholar
  17. 17.
    Newman MG, Takei HH, Klokkevold PR, Carranza FA (2011) Carranza’s clinical periodontology. Saunders Elsevier, St. LouisGoogle Scholar
  18. 18.
    Norderyd OM, Grossi SG, Machtei EE et al (1993) Periodontal status of women taking postmenopausal estrogen supplementation. J Periodontol 64:957–962PubMedCrossRefGoogle Scholar
  19. 19.
    Reinhardt RA, Payne JB, Maze CA et al (1999) Influence of estrogen and osteopenia/osteoporosis on clinical periodontitis in postmenopausal women. J Periodontol 70:823–828PubMedCrossRefGoogle Scholar
  20. 20.
    Pizzo G, Guiglia R, Licata ME et al (2011) Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women. Med Sci Monit 17:PH23–PH27PubMedGoogle Scholar
  21. 21.
    Grossi SG (1998) Effect of estrogen supplementation on periodontal disease. Compend Contin Educ Dent Suppl:S30–S36Google Scholar
  22. 22.
    Ronderos M, Jacobs DR, Himes JH et al (2000) Associations of periodontal disease with femoral bone mineral density and estrogen replacement therapy: cross-sectional evaluation of US adults from NHANES III. J Clin Periodontol 27:778–786PubMedCrossRefGoogle Scholar
  23. 23.
    Haas AN, Rosing CK, Oppermann RV et al (2009) Association among menopause, hormone replacement therapy, and periodontal attachment loss in southern Brazilian women. J Periodontol 80:1380–1387PubMedCrossRefGoogle Scholar
  24. 24.
    Lopez-Marcos JF, Garcia-Valle S, Garcia-Iglesias AA (2005) Periodontal aspects in menopausal women undergoing hormone replacement therapy. Med Oral Patol Oral Cir Bucal 10:132–141PubMedGoogle Scholar
  25. 25.
    Evio S, Tarkkila L, Sorsa T et al (2006) Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. Oral Dis 12:187–193PubMedCrossRefGoogle Scholar
  26. 26.
    Payne JB, Zachs NR, Reinhardt RA et al (1997) The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. J Periodontol 68:24–31PubMedCrossRefGoogle Scholar
  27. 27.
    Civitelli R, Pilgram TK, Dotson M et al (2002) Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 162:1409–1415PubMedCrossRefGoogle Scholar
  28. 28.
    Grodstein F, Colditz GA, Stampfer MJ (1996) Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc 127:370–377; quiz 392PubMedGoogle Scholar
  29. 29.
    Krall EA (2006) Osteoporosis and the risk of tooth loss. Clin Calcium 16:287–290PubMedGoogle Scholar
  30. 30.
    Krall EA, Dawson-Hughes B, Hannan MT et al (1997) Postmenopausal estrogen replacement and tooth retention. Am J Med 102:536–542PubMedCrossRefGoogle Scholar
  31. 31.
    Paganini-Hill A (1995) The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Arch Intern Med 155:2325–2329PubMedCrossRefGoogle Scholar
  32. 32.
    Albandar JM, Streckfus CF, Adesanya MR et al (2000) Cigar, pipe, and cigarette smoking as risk factors for periodontal disease and tooth loss. J Periodontol 71:1874–1881PubMedCrossRefGoogle Scholar
  33. 33.
    Krall EA, Dawson-Hughes B, Garvey AJ et al (1997) Smoking, smoking cessation, and tooth loss. J Dent Res 76:1653–1659PubMedCrossRefGoogle Scholar
  34. 34.
    Taguchi A, Sanada M, Suei Y et al (2004) Effect of estrogen use on tooth retention, oral bone height, and oral bone porosity in Japanese postmenopausal women. Menopause 11:556–652PubMedCrossRefGoogle Scholar
  35. 35.
    Megson E, Kapellas K, Bartold PM (2011) Relationship between periodontal disease and osteoporosis. Int J Evid Based Healthc 8:129–139CrossRefGoogle Scholar
  36. 36.
    Payne JB, Reinhardt RA, Nummikoski PV et al (1999) Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 10:34–40PubMedCrossRefGoogle Scholar
  37. 37.
    Klemetti E, Kolmakov S, Kroger H (1994) Pantomography in assessment of the osteoporosis risk group. Scand J Dent Res 102:68–72PubMedGoogle Scholar
  38. 38.
    Al Habashneh R, Alchalabi H, Khader YS et al (2011) Association between periodontal disease and osteoporosis in postmenopausal women in Jordan. J Periodontol 81:1613–1621CrossRefGoogle Scholar
  39. 39.
    Nicopoulou-Karayianni K, Tzoutzoukos P, Mitsea A et al (2009) Tooth loss and osteoporosis: the OSTEODENT study. J Clin Periodontol 36:190–197PubMedCrossRefGoogle Scholar
  40. 40.
    Tezal M, Wactawski-Wende J, Grossi SG et al (2005) Periodontal disease and the incidence of tooth loss in postmenopausal women. J Periodontol 76:1123–1128PubMedCrossRefGoogle Scholar
  41. 41.
    Krall EA, Dawson-Hughes B, Papas A et al (1994) Tooth loss and skeletal bone density in healthy postmenopausal women. Osteoporos Int 4:104–109PubMedCrossRefGoogle Scholar
  42. 42.
    Kribbs PJ (1990) Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 63:218–222PubMedCrossRefGoogle Scholar
  43. 43.
    Takaishi Y, Okamoto Y, Ikeo T et al (2005) Correlations between periodontitis and loss of mandibular bone in relation to systemic bone changes in postmenopausal Japanese women. Osteoporos Int 16:1875–1882PubMedCrossRefGoogle Scholar
  44. 44.
    Valimaa H, Savolainen S, Soukka T et al (2004) Estrogen receptor-beta is the predominant estrogen receptor subtype in human oral epithelium and salivary glands. J Endocrinol 180:55–62PubMedCrossRefGoogle Scholar
  45. 45.
    Wardrop RW, Hailes J, Burger H et al (1989) Oral discomfort at menopause. Oral Surg Oral Med Oral Pathol 67:535–540PubMedCrossRefGoogle Scholar
  46. 46.
    Streckfus CF, Baur U, Brown LJ et al (1998) Effects of estrogen status and aging on salivary flow rates in healthy Caucasian women. Gerontology 44:32–39PubMedCrossRefGoogle Scholar
  47. 47.
    Mott AE, Grushka M, Sessle BJ (1993) Diagnosis and management of taste disorders and burning mouth syndrome. Dent Clin North Am 37:33–71PubMedGoogle Scholar
  48. 48.
    Lopez-Jornet P, Camacho-Alonso F, Andujar-Mateos P et al (2010) Burning mouth syndrome: an update. Med Oral Patol Oral Cir Bucal 15:e562–e568PubMedCrossRefGoogle Scholar
  49. 49.
    Ferris GM (1993) Alteration in female sex hormones: their effect on oral tissues and dental treatment. Compendium 14:1558–15564, 1566; quiz 1571PubMedGoogle Scholar
  50. 50.
    Zakrzewska JM (1996) Women as dental patients: are there any gender differences? Int Dent J 46:548–557PubMedGoogle Scholar
  51. 51.
    Zakrzewska JM, Glenny AM, Forssell H (2001) Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 1:CD002779Google Scholar
  52. 52.
    Gao J, Chen L, Zhou J et al (2009) A case-control study on etiological factors involved in patients with burning mouth syndrome. J Oral Pathol Med 38:24–28PubMedCrossRefGoogle Scholar
  53. 53.
    Forabosco A, Criscuolo M, Coukos G et al (1992) Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surg Oral Med Oral Pathol 73:570–574PubMedCrossRefGoogle Scholar
  54. 54.
    Scala A, Checchi L, Montevecchi M et al (2003) Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 14:275–279PubMedCrossRefGoogle Scholar
  55. 55.
    Mock D, Chugh D (2010) Burning mouth syndrome. Int J Oral Sci 2:1–4PubMedCrossRefGoogle Scholar
  56. 56.
    Hadji P, Ziller M, Maskow C et al (2009) The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 45:3205–3212PubMedCrossRefGoogle Scholar
  57. 57.
    Robinson WR, Luck M, Omar H et al (2005) A pilot study of bone density loss in menopausal women treated with chemotherapy for cancer. Support Care Cancer 13:663–667PubMedCrossRefGoogle Scholar
  58. 58.
    Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365:62–70PubMedCrossRefGoogle Scholar
  59. 59.
    von Wowern N, Klausen B, Olgaard K (1992) Steroid-induced mandibular bone loss in relation to marginal periodontal changes. J Clin Periodontol 19:182–186CrossRefGoogle Scholar
  60. 60.
    Van Poznak C, Sauter NP (2005) Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 104:443–456PubMedCrossRefGoogle Scholar
  61. 61.
    VanderWalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61:139–156PubMedCrossRefGoogle Scholar
  62. 62.
    Santen RJ (2011) Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 96:308–319PubMedCrossRefGoogle Scholar
  63. 63.
    Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796PubMedCrossRefGoogle Scholar
  64. 64.
    Gralow JR, Biermann JS, Farooki A et al (2009) NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 7 Suppl 3:S1–S32; quiz S33-S35PubMedGoogle Scholar
  65. 65.
    Love RR, Mazess RB, Barden HS et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856PubMedCrossRefGoogle Scholar
  66. 66.
    Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78–84PubMedGoogle Scholar
  67. 67.
    Soory M, Tilakaratne A (2003) Modulation of androgen metabolism by phenytoin, oestradiol and tamoxifen in human gingival fibroblasts. J Clin Periodontol 30:556–561PubMedCrossRefGoogle Scholar
  68. 68.
    Tilakaratne A, Soory M (1999) Modulation of androgen metabolism by estradiol-17beta and progesterone, alone and in combination, in human gingival fibroblasts in culture. J Periodontol 70:1017–1025PubMedCrossRefGoogle Scholar
  69. 69.
    U.S. National Institutes of Health Clinical Trials Registry. Accessed 1 April 2012
  70. 70.
    Watters AL, Epstein JB, Agulnik M (2011) Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 47:441–448PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • L. Susan Taichman
    • 1
  • Aaron M. Havens
    • 1
    • 2
  • Catherine H. Van Poznak
    • 3
  1. 1.Department of Periodontics and Oral MedicineUniversity of Michigan School of DentistryAnn ArborUSA
  2. 2.Department of Orthodontics and Pediatric DentistryUniversity of Michigan School of DentistryAnn ArborUSA
  3. 3.Division of Hematology and Oncology, Department of Internal MedicineUniversity of MichiganAnn ArborUSA

Personalised recommendations